98%
921
2 minutes
20
We developed a fast and fully-automated, multi-criteria treatment planning workflow for high dose rate brachytherapy (HDR-BT). In this workflow, the patient-CT with catheter reconstructions and dwell positions are imported from the clinical TPS into a novel system for automated dwell time optimisation. The optimised dwell times are then imported into the clinical TPS. The aims of automation were (1) planner-independent, enhanced plan quality, (2) short optimisation times. Our in-house developed system for fully automated, multi-criteria external beam radiotherapy (EBRT) treatment planning (Erasmus-iCycle) was adapted for optimisation of HDR-BT dose distributions. The investigations were performed with planning CT scans with catheter reconstructions and delineations of twenty-five low- and intermediate-risk prostate cancer patients who were previously treated in our center with [Formula: see text] Gy HDR-BT. Automatically generated plans (autoplans) were compared to the corresponding clinical plans. All evaluations were performed in the clinical TPS. The requested 95% tumour coverage was obtained for all autoplans, while this was only observed in 23/25 clinical plans. All autoplans showed a consistent reduction of the [Formula: see text] for the highest prioritised OAR, the urethra. The average and maximum reductions were 6.3%-point and 12.1%-point of the prescribed dose, respectively. In addition, conformality of the autoplans was higher. The autoplans had slightly smaller delivery times. Autoplanning took on average 4.6 s, including computation of the dose kernels.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1088/1361-6560/ab44ff | DOI Listing |
J Cancer Res Clin Oncol
September 2025
Cancer Treatment and Nuclear Cardiology Department, Al Azhar University, Cairo, Egypt.
Background: High-dose-rate (HDR) brachytherapy is essential in the treatment of locally advanced cervical cancer. While Iridium-192 (Ir-192) is commonly used, its short half-life imposes logistical and financial constraints, particularly in low- and middle-income countries (LMICs). Cobalt-60 (Co-60), with a longer half-life and lower operational costs, is a viable alternative.
View Article and Find Full Text PDFDig Endosc
September 2025
Gastrointestinal Endoscopy Unit, Division of Gastroenterology, Hospital das Clínicas of the Faculty of Medicine of the University of São Paulo - HC/FMUSP, São Paulo, Brazil.
Background: Difficult biliary cannulation is a key challenge in endoscopic retrograde cholangiopancreatography and a major risk factor for post-ERCP pancreatitis. When the pancreatic duct is unintentionally accessed, double guidewire (DGW) is the primary rescue strategy, while transpancreatic sphincterotomy (TPS) is an alternative. Previous evidence suggests that TPS may achieve higher cannulation success and lower PEP rates compared to DGW, though direct comparative data remain limited.
View Article and Find Full Text PDFHistopathology
September 2025
Institute of Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm, Ulm, Germany.
Background: Given that pathologists now frequently assess pathologic response following neoadjuvant or perioperative chemoimmunotherapy for NSCLC, we set up a multicentre study to evaluate the current practice of regression grading in Germany (Re-GraDE NSCLC).
Methods: 133 cases of NSCLC resection specimens following chemoimmunotherapy (IO) were collected from 9 high-volume lung cancer centres in Germany. Case characteristics were obtained from pathology reports/electronic medical records.
Immunotherapy
August 2025
Department of Medical Oncology, Fortrea Inc., Durham, NC, USA.
Introduction: Pembrolizumab is a standard first-line therapy for advanced/metastatic non-small cell lung cancer (a/mNSCLC) lacking actionable mutations. Data from lower-middle-income countries (LMICs) remain scarce.
Methods: From January 2019 to June 2024, we prospectively analyzed 78 a/mNSCLC patients receiving pembrolizumab-based first-line therapy.
Front Oncol
August 2025
Department of Radiological Sciences, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia.
Introduction: The accuracy of dose delivery in radiotherapy is paramount to maximize tumor control while minimizing damage to surrounding healthy tissues. This study presents a comprehensive analysis of gamma index validation in the treatment of cancerous tumors using Monte Carlo simulations with GAMOS and GATE codes on a Varian medical linear accelerator. By leveraging the MC method's robust statistical capabilities, the precision of dose distributions in external radiotherapy is aimed to be enhanced.
View Article and Find Full Text PDF